GHK-Cu Dosing in Hepatic Impairment: What Clinicians Need to Know

Is there a GHK-Cu dose for hepatic impairment?

No GHK-Cu dose has been established for anyone, with or without liver disease: there is no FDA-approved GHK-Cu dose or product [1][2]. Topical copper peptide cosmetics do not require FDA approval before sale [4]; one venous ulcer trial tested a 0.4% copper tripeptide cream [6]. An injectable GHK-Cu product is not a cosmetic and is not FDA-approved [1][4].

FDA has a draft guidance on how sponsors should study the effect of hepatic impairment on a drug's pharmacokinetics [7].

What the cupric chloride label says

Copper (cupric chloride) injection is an FDA-approved intravenous additive for total parenteral nutrition [3]. It is not GHK-Cu. The label warns that copper is primarily eliminated in bile and excretion is decreased in cholestasis and/or cirrhosis, and that hepatic accumulation has been reported at autopsy after long-term parenteral nutrition with copper above recommended doses [3]. It says copper may accumulate in Wilson disease and aggravate underlying hepatocellular degeneration [3]. The label directs monitoring of hepatic and biliary function in patients with cholestasis, biliary dysfunction or cirrhosis during long-term administration, and obtaining serum copper and ceruloplasmin if hepatobiliary signs or symptoms appear [3].

Copper retention in other liver disease

Wilson disease is a rare autosomal-recessive copper overload disorder caused by ATP7B mutations [8]. In 70 patients with primary sclerosing cholangitis, hepatic copper was elevated in 87%, with mean hepatic copper of 147 mcg/g dry weight in stages I–II and 379 mcg/g in stage IV; 24-hour urinary copper was elevated in 64% [9]. That describes how a diseased liver holds copper; it does not supply a GHK-Cu dose adjustment.

What human GHK-Cu evidence exists

In a randomized trial of topical GHK-Cu after carbon dioxide laser resurfacing, 13 patients completed [10]. Computer analysis and blinded evaluators found no significant difference in redness, wrinkles or overall skin quality; a patient questionnaire favored GHK-Cu for overall skin quality (P=.04) [10].

In the venous ulcer trial, 86 evaluable patients completed the study. The 0.4% copper tripeptide cream was no different from placebo for ulcer size, while silver sulfadiazine 1% reduced it [6]. A 2026 systematic review retained 64 of 1,247 records and concluded that the human literature is thin and fragmented [11].

Regulatory status and monitoring

Injectable GHK-Cu is in FDA's table of bulk substances nominated but withdrawn; FDA states that compounded injectable drugs containing it may pose an immunogenicity risk from aggregation and peptide-related impurities, with limited human data [5]. Non-injectable GHK-Cu is under FDA evaluation for its bulk-substances list [1][12]. Compounded drugs are not FDA-approved [13].

No GHK-Cu-specific monitoring schedule has been established. The cupric chloride injection label gives a normal serum copper range of 80 to 163 mcg/dL, but it is not a GHK-Cu testing schedule [3].